Characterization of Human Papillomavirus prevalence and risk factors to guide cervical cancer screening in the North Tongu District, Ghana

被引:48
|
作者
Krings, Amrei [1 ,2 ,3 ,4 ]
Dunyo, Priscilla [5 ]
Pesic, Aleksandra [1 ,2 ,3 ,4 ]
Tetteh, Saviour [5 ]
Hansen, Benjamin [5 ]
Gedzah, Isaac [5 ]
Wormenor, Comfort M. [5 ]
Amuah, Joseph E. [6 ]
Behnke, Anna-Lisa [1 ,2 ,3 ,4 ]
Hofler, Daniela [7 ]
Pawlita, Michael [7 ]
Kaufmann, Andreas M. [1 ,2 ,3 ,4 ]
机构
[1] Charite Univ Med Berlin, Clin Gynecol, Lab Gynecol Tumor Immunol, Campus Benjamin Franklin, Berlin, Germany
[2] Free Univ Berlin, Campus Benjamin Franklin, Berlin, Germany
[3] Humboldt Univ, Campus Benjamin Franklin, Berlin, Germany
[4] Berlin Inst Hlth, Campus Benjamin Franklin, Berlin, Germany
[5] Catholic Hosp Battor, Battor, Volta Region, Ghana
[6] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada
[7] German Canc Res Ctr, Res Program Infect Inflammat & Canc, Div Mol Diagnost Oncogen Infect, Heidelberg, Germany
来源
PLOS ONE | 2019年 / 14卷 / 06期
关键词
INFECTION; WOMEN; HPV; HIV;
D O I
10.1371/journal.pone.0218762
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction This population-based study aimed to fill the knowledge gap on Human Papillomavirus (HPV) prevalence and associated sociodemographic risk factors of the general population in the North Tongu District, Ghana. These results are needed to guide cervical cancer prevention efforts, as the leading type of female cancers. Methods A cross-sectional study including 2002 women in the North Tongu District, Ghana investigated HPV prevalence and associated sociodemographic risk factors. Women were recruited by geographical distribution through the local community-based health system and samples collected using a self-sampling device. For HPV genotyping BSGP5+/6+-PCR with Luminex-MPG readout was used. Multivariate logistic regression analyzed sociodemographic risk factors for HPV positivity. Results Of 2002 self-collected samples, 1943 were eligible, contained sufficient DNA and provided valid HPV genotyping results. Prevalence of single high risk HPV types was 32.3% and of multiple high risk types 9.7%. The five most common detected HPV types were HPV16 (7.4%; 95% CI: 6.3-8.7), HPV52 (7.2%; 95% CI: 6.1-8.5), HPV35 (4.8%; 95% CI: 3.9-5.8), HPV59 (4.7%; 95% CI: 3.8-5.8), HPV56 (3.9%; 95% CI: 3.1-4.8). Highest prevalence was observed among women aged 18-24 years, while age 25-54 years was inversely associated with high risk HPV positivity in multivariate analysis. Sociodemographic risk factors identified were i) having any sexual partner, ii) more partners increased the odds for high risk HPV positivity, iii) independently from this marital status, in particular not being married. Discussion & conclusion Most importantly, the high risk HPV prevalence detected from this study is higher than estimates reported for Western Africa. This needs be considered, when deciding on the cervical cancer screening algorithms introduced on a wider scale. Follow-up and triage, depending on the methods chosen, can easily overburden the health system. Self-sampling worked well and provided adequate samples for HPV-based screening. Women with increasing number of sexual partners and not being married were found to have higher odds of being high risk HPV positive, therefore could be a higher prioritized screening target group.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Role of human papillomavirus genotyping in cervical cancer screening
    Andujar-Sanchez, Miguel
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2023, 41 (05): : 259 - 261
  • [32] Human papillomavirus testing for primary cervical cancer screening
    Grce, Magdalena
    Davies, Philip
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2008, 8 (05) : 599 - 605
  • [33] Cervical cancer screening in the time of the human papillomavirus vaccine
    Sheinfeld, Gorin S.
    Franco, R.
    Hajiani, F.
    Westhoff, C.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (02) : 358 - 358
  • [34] Human papillomavirus vaccines versus cervical cancer screening
    Stantey, M.
    CLINICAL ONCOLOGY, 2008, 20 (06) : 388 - 394
  • [35] Human papillomavirus testing for primary cervical cancer screening
    Carolyn D. Runowicz
    Stephanie Garozzo
    Current Oncology Reports, 2008, 10
  • [36] The application of human papillomavirus testing to cervical cancer screening
    Lee, HP
    Seo, SS
    YONSEI MEDICAL JOURNAL, 2002, 43 (06) : 763 - 768
  • [37] Human Papillomavirus Testing for Primary Cervical Cancer Screening
    Runowicz, Carolyn D.
    Garozzo, Stephanie
    CURRENT ONCOLOGY REPORTS, 2008, 10 (06) : 533 - 537
  • [38] Accelerating Cervical Cancer Screening With Human Papillomavirus Genotyping
    Sawaya, George F.
    Saraiya, Mona
    Soman, Ashwini
    Gopalani, Sameer, V
    Kenney, Kristy
    Miller, Jacqueline
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2023, 64 (04) : 552 - 555
  • [39] Human papillomavirus testing for primary cervical cancer screening
    Cuzick, J
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (01): : 108 - 109
  • [40] Human Papillomavirus DNA Testing for Cervical Cancer Screening
    Belinson, Suzanne E.
    Belinson, Jerome L.
    MOLECULAR DIAGNOSIS & THERAPY, 2010, 14 (04) : 215 - 222